SMMT Summit Therapeutics PLC
Company Analysis
Latest News
Summit Therapeutics PLC Q3 2026 Earnings Preview: What Analysts Expect on November 09, 2026
Wall Street analysts expect Summit Therapeutics to report a Q3 2026 consensus revenue of $0.11 million and a net loss of $0.28 per share, while the stock...
🟢 Summit Therapeutics is trading 11% up today as broader markets recover
Summit Therapeutics is trading 10.50% up at $15.68, with the broader market recovery the clearest explanation for the move. - The stock rebounded after its...
🟢 Summit Therapeutics is trading 5% up
Summit Therapeutics is trading at $14.92, up 5.14%, rebounding after its November 5 close of $14.19. - No clear November 6 company-specific announcement was...
🔴 Summit Therapeutics is trading 11% down today as biotech and major indexes sell off
Summit Therapeutics is trading at $14.46, down 10.61%, amid broad market and biotech weakness. - The company reported a third-quarter GAAP net loss of $208.4...
🔴 Summit Therapeutics is trading 5% down
Summit Therapeutics is trading 5.07% lower at $15.28 on November 5, 2026; available information does not establish a specific cause for the decline. -...
Summit Therapeutics third quarter 2026 net loss of $208M precedes $2B AstraZeneca equity investment
Summit Therapeutics reported a GAAP net loss of $208.4 million for the third quarter of 2026, as the company prepares for a critical regulatory decision...
Summit Therapeutics Files Prospectus for Potential Resale of 108.9M Shares
Summit Therapeutics filed a prospectus supplement for the potential resale of up to 108,955,369 shares of its common stock by a selling stockholder. The shares...
🟢 Summit Therapeutics is trading 10.4% up today amid broader biotech strength
Summit Therapeutics is trading at $16.34, up 10.41%, with broader biotech strength supporting a sector-driven explanation for the move. - No clear...
🟢 Summit Therapeutics is trading 5% up today amid gains in biotech ETF XBI
Summit Therapeutics is trading 5% higher at $15.54 on November 3, amid strength across biotech stocks. - Biotech ETF XBI is up 2.13% during the regular...
🔴 Summit Therapeutics is trading 4.37% down
Summit Therapeutics is trading 4.37% lower at $15.33, with no confirmed catalyst identified for the November 2 decline. - The stock is falling while major U.S....
Summit Therapeutics PLC Q3 2026 Earnings Preview: What Analysts Expect on November 02, 2026
For the third quarter of 2026, Wall Street expects Summit Therapeutics to report a net loss of $0.28 per share on zero revenue, with the stock trading at...
🟢 Summit Therapeutics is trading 4.07% up today after Akeso reports positive Phase III survival results
Summit Therapeutics is trading at $15.09, up 4.07%, after partner Akeso reported positive Phase III overall-survival results for ivonescimab plus chemotherapy...
Summit Therapeutics Reports Phase III Ivonescimab Survival Gain in Biliary Cancer
Summit Therapeutics announced positive overall survival results from the Phase III HARMONi-GI1 trial of investigational cancer drug ivonescimab. The findings...
🔴 Summit Therapeutics is trading 4.65% down today after HARMONi's 21% survival improvement lacked statistical significance
Summit Therapeutics is trading 4.65% lower at $14.75, with a likely company-specific overhang from October 25 HARMONi lung-cancer trial results: the reported...
Summit Therapeutics PLC Q3 2026 Earnings Preview: What Analysts Expect on October 26, 2026
Consensus estimates for Summit Therapeutics point to a Q3 2026 loss of $0.28 per share on minimal revenue of approximately $0.05 million, while the current...
Summit Starts Phase II/III Trial of Ivonescimab for First-Line Biliary Cancer
Summit Therapeutics and partner Akeso Inc. have initiated EA2251, a Phase II/III study evaluating ivonescimab as a first-line treatment for advanced biliary...
🔴 Summit Therapeutics is trading 5% down in pre-market amid S&P 500 and Nasdaq declines
Summit Therapeutics is trading at $15.02, down 5.10%, with broad risk-off sentiment potentially contributing. - The S&P 500 was down 1.11% and the Nasdaq...
Summit Therapeutics Proposes Doubling Authorized Shares to Support Preferred Conversion
Summit Therapeutics has proposed an amendment to its charter that would double the number of authorized common shares from 1 billion to 2 billion. Shareholders...
🟢 Summit Therapeutics is trading 5% up today amid broader market rebound
Summit Therapeutics is trading at $15.39, up 5.19%; no direct cause for the move is established. - On October 19, the company announced a global Phase II...
Summit Therapeutics PLC Q3 2026 Earnings Preview: What Analysts Expect on October 19, 2026
Summit Therapeutics is expected to report a Q3 2026 net loss of $0.28 per share on zero revenue, as the stock trades at $21.42 against a bullish consensus...